Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results